Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.48 (
transcriptase
)
9,479
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cystatin M is a secreted inhibitor of lysosomal cysteine proteases and increasing evidences indicate that it is a novel target for epigenetic silencing during mammary tumorigenesis. Aberrant promoter methylation is a well-known mechanism that participates in
cystatin M
silencing in breast cancer. However, the role of
cystatin M
in the gastric cancer remains to be elucidated. Immunohistochemistry was used to investigate the expression of
cystatin M
in 60 gastric carcinomas. Hypermethylation of
cystatin M
promoter was evaluated by the methylation-specific PCR (MSP) method in gastric carcinomas (tumor and paired adjacent non-tumor tissues). Reverse-
transcriptase
PCR and BSP were also performed on gastric cancer cell lines before and after treatment with 5-aza-2'-deoxycytidine (5-Aza-dC). Lost expression of
cystatin M
was observed in 42 of 60 (70%) gastric carcinomas. 55% (33 of 60) of primary tumors analyzed displayed
cystatin M
promoter hypermethylation, indicating that this aberrant characteristic is common in gastric malignancies. Moreover, a statistically significant inverse association was found between
cystatin M
methylation status and expression of the
cystatin M
protein in tumor tissues (p=0.027). We also found that patients with
cystatin M
promoter methylation had a significantly shorter survival time than those without this methylation (p=0.020). These results suggest that
cystatin M
promoter hypermethylation is one of the molecular mechanisms that accounts for reduced
cystatin M
gene expression in gastric carcinomas.
...
PMID:Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation. 2000 78
